Vicebio has raised $100m in a Series B funding round led by TCGX. Credit: MargJohnsonVA via Shutterstock. UK-based startup ...
A new dose-finding study supported the potential of the carbonic anhydrase inhibitor as an alternative to CPAP machines.
Nevada U.S. Senator Jacky Rosen, Colleagues File Amicus Brief Urging Court to Uphold Medicare’s Ability to Negotiate Lower ...
A dark money anti-pharma bus —A rare disease treatment approval for Zevra —An FTC lawsuit against pharmacy benefit managers ...
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...
Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second quarter 2024 ...
It said the drug did not 'achieve statistical significance' in terms of the survival rates of those suffering from breast ...
Intel jumps on reports of Apollo investment and Qualcomm takeover interest, Palantir and Dell join the S&P 500, and TSMC and Samsung reportedly mulling UAE chip megafactories. Here's what investors ...
AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically ...
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...
AstraZeneca, Daiichi’s TROP2 drug misses overall survival goal in Phase 3 breast cancer trial
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate failed a key survival endpoint in a late-phase breast ...
Cerulean Ventures, a climate tech venture capital firm in Santa Barbara, Calif,, closed a $10 million pre-seed fund to work ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback